About Galectin-8
Galectin-8 (LGALS8) is a protein
from Homo sapiens identified by UniProt accession
O00214, 317 residues long.
MolForge cross-references it against 0 known binders and
183 disease associations.
Target properties
| Protein name | Galectin-8 |
|---|
| UniProt accession | O00214 |
|---|
| Gene | LGALS8 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 317 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (183)
Diseases linked to this target (Open Targets).
- platelet component distribution width · score 0.29
- platelet count · score 0.27
- total cholesterol measurement · score 0.26
- platelet crit · score 0.21
- alcohol consumption measurement · score 0.20
- aspartate aminotransferase measurement · score 0.19
- neoplasm · score 0.11
- hypothyroidism · score 0.10
- attention deficit hyperactivity disorder · score 0.09
- thyroid disease · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O00214-F1 | alphafold | PREDICTED | 90.68 | — |
Amino-acid sequence (317 residues)
MMLSLNNLQN IIYNPVIPFV GTIPDQLDPG TLIVIRGHVP SDADRFQVDL QNGSSMKPRA DVAFHFNPRF KRAGCIVCNT LINEKWGREE ITYDTPFKRE KSFEIVIMVL KDKFQVAVNG KHTLLYGHRI GPEKIDTLGI YGKVNIHSIG FSFSSDLQST QASSLELTEI SRENVPKSGT PQLRLPFAAR LNTPMGPGRT VVVKGEVNAN AKSFNVDLLA GKSKDIALHL NPRLNIKAFV RNSFLQESWG EEERNITSFP FSPGMYFEMI IYCDVREFKV AVNGVHSLEY KHRFKELSSI DTLEINGDIH LLEVRSW
Explore Galectin-8 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets